Discussion around the choice of SGLT2 inhibitor has been again revived by the recent publication of results from the VERTIS-CV, EMPEROR-reduced and DAPA-CKD trials investigating cardiovascular, heart failure and renal outcomes associated with various SGLT2 inhibitors. This narrative review gives an ...
Dapagliflozin’s tolerability profile was also generally consistent with previous SGLT2 inhibitor trials, with no new safety signals identified. Reassuringly, we did not observe any events of DKA or severe hypoglycemia (although about half of the patients did not have T2D and the duration of the...
These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes. April 2022: Nippon Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin) obtained a label update from PMDA in Japan, allowing its use in patients with chronic heart failure with ...
A novel class of anti-diabetes therapy known as the sodium glucose-linked cotransporter subtype 2 (SGLT2) inhibitor has shown potential in addressing this area of urgent unmet need, not only by improving glycaemia but also preserving renal function and reducing hard HF outcomes as well. In this...
Sotagliflozin is the first dual SGLT1/2 receptor inhibitor, that was shown to significantly reduce atherothrombotic events compared with placebo in diabetic HF patients, suggesting that dual SGLT1/2 inhibitor may have additional properties vs. SGLT2-i. The hypothesis of this study is that dual ...
Chronic kidney disease (CKD) is a major public health issue and an independent risk factor for cardiovascular and all-cause mortality. Diabetic kidney disease develops in 30–50% of diabetic patients and it is the leading cause of end-stage renal disease
SGLT2inhibitor use in the management of feline diabetes mellitus Review 作者:Cook, Audrey K.;Behrend, Ellen Abstract: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are routinely used in the management of human type 2 diabetes and have been shown to effectively mitigate hyperglycemia and reduce...
DPP4i = dipeptidyl peptidase 4 inhibitor; EXAMINE = Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes; SAVOR-TIMI 53 = Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus-Thrombolysis In Myocardial Infarction 53; TECOS = Effect of Sitagliptin on...
We present two cases of inpatient SGLT2 inhibitor use, one of continuation of outpatient therapy and one of new initiation of therapy. We then discuss potential risks and methods to mitigate these as well as benefits of these medications in the inpatient setting. Summary We cautiously suggest ...
In contrast to other antidiabetic medications, SGLT2i are insulin-independent. Pancreatic β-cells are not overstimulated to secrete excessive insulin; thus, there is a lower risk of hypoglycemia. The SGLT2i mechanism is based solely on the renal glomerular tubular function. Therefore, reduced ...